drugset / Trial / NCT07328841

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

NCT07328841

Phase 3 Recruiting 456 enrolled Ming-Yuan Chen
RandomizedParallel-groupOpen-labelTreatment

Summary

To explore the efficacy and safety of reduced-dose radiotherapy combined with concurrent chemotherapy and immunotherapy in stage Ⅳa (AJCC 8th,) locally advanced nasopharyngeal carcinoma patients who are sensitive to induction chemoimmunotherapy (assessed as complete response \[CR\]/partial response \[PR\] by imaging, with EBV DNA copy number reduced to zero or below the lower limit of detection), so as to provide a new treatment option for these patients.

Timeline

Start
2025-11-18
Primary completion
2030-06-30
Completion
2032-06-30

Drugs

EvaluationDrugModalityDoseRoute
Background Cisplatin Other / unclassified 100 mg/m2
Background Toripalimab Monoclonal antibody 240 mg Intravenous